Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Number 7,964,563 for Prolactin
23 June 2011 - 2:03AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") announces today that a patent by the U.S. Patent and
Trademark Office -U.S. Patent 7,964,563 was granted today. The
patent is entitled, "Oligodendrocyte Precursor Cell Proliferation
Regulated By Prolactin." Claims granted in this Stem Cell
Therapeutics Corp/ Patent focus protecting the therapeutic use of
Prolactin for Multiple Sclerosis.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as
follows:
"We are very pleased by the granting of this patent, as it
represents a cornerstone achievement in SCT's strategy to protect
the use of prolactin for treating central nervous system disorders
that involve white matter, and specifically for the treatment of
Multiple Sclerosis. This patent builds upon the strong basic
scientific evidence that prolactin possesses the ability to
stimulate endogenous stem cells to increase oligodendrocytes
precursor cells in animals with central nervous system injuries and
importantly increase the amount of myelin in white matter lesions.
The anticipated MS clinical trial for the prolactin development
program will substantially advance SCT's understanding how this
important, novel neuro-regenerative therapy affects recovery in MS
patients."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as Stroke,
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO
403-245-5495 ext.226 adavidoff@stemcellthera.com Stem Cell
Therapeutics Corp. Michael Cook CFO 403-245-5495 ext.229
mcook@stemcellthera.com www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024